tiprankstipranks
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) AI Stock Analysis

Compare
2,345 Followers

Top Page

CR

Corbus Pharmaceuticals

(NASDAQ:CRBP)

32Underperform
Corbus Pharmaceuticals is challenged by severe financial instability with no recent revenue and ongoing losses. The technical outlook is bearish, with the stock showing strong downward momentum. While a promising Phase 1 trial result offers hope, the immediate financial and technical concerns weigh heavily on the stock's overall score.
Positive Factors
Financial Performance
Corbus reported a net loss that was better than both the analyst's and consensus estimates, driven primarily by lower-than-expected R&D and SG&A expenses.
Regulatory Approval
The FDA granted Fast Track designation for CRB-701 in relapsed or refractory metastatic cervical cancer.
Negative Factors
Market Sentiment
The short interest in Corbus Pharmaceuticals is 23.2% of the float, indicating a significant portion of the market is betting against the stock.

Corbus Pharmaceuticals (CRBP) vs. S&P 500 (SPY)

Corbus Pharmaceuticals Business Overview & Revenue Model

Company DescriptionCorbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
How the Company Makes MoneyCorbus Pharmaceuticals primarily makes money through the development and commercialization of its drug candidates. The company's revenue model involves advancing its drug pipeline through clinical trials, obtaining regulatory approvals, and subsequently partnering with larger pharmaceutical companies for distribution and commercialization. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and potential sales of its proprietary drugs once approved. Corbus relies on collaborations with other pharmaceutical companies and research institutions to enhance its research capabilities and expedite the development of its therapeutic candidates, which is crucial for generating future revenue.

Corbus Pharmaceuticals Financial Statement Overview

Summary
Corbus Pharmaceuticals faces significant financial challenges, particularly in profitability with negative profit margins and cash flow generation issues. Despite improvements in stockholders' equity, high operating losses and reliance on external funding remain concerns.
Income Statement
45
Neutral
Corbus Pharmaceuticals' income statement reflects significant challenges in profitability. The TTM (Trailing-Twelve-Months) data shows a gross profit margin of 63%, which is positive. However, both the net profit margin and EBIT margin are highly negative, indicating substantial losses. Revenue growth is not applicable as previous periods reported zero revenue. The company needs to address its high operating losses to improve its financial health.
Balance Sheet
50
Neutral
The balance sheet shows a high debt-to-equity ratio, primarily driven by negative equity in previous periods. Current data shows improved equity, but the leverage remains a concern. The equity ratio is robust due to a significant increase in stockholders' equity. Although the company has improved its equity position recently, the high historical leverage poses risks to financial stability.
Cash Flow
40
Negative
Cash flow analysis reveals a challenging scenario for Corbus Pharmaceuticals. The company has consistently negative free cash flow, and the operating cash flow to net income ratio is unfavorable, indicating cash flow issues. While there was a significant financing cash flow in the TTM period, reliance on external funding is not sustainable. The company must improve operational efficiency to generate positive cash flows.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
1.35M0.000.00881.71K3.94M36.14M
Gross Profit
850.12K-31.17M-1.49M-757.53K3.84M36.05M
EBIT
-46.22M-45.08M-39.84M-55.99M-122.81M-77.10M
EBITDA
-41.82M-44.44M-38.73M-54.97M-121.69M-76.37M
Net Income Common Stockholders
-38.70M-44.60M-55.83M-45.55M-111.30M-69.15M
Balance SheetCash, Cash Equivalents and Short-Term Investments
41.75M20.91M59.20M97.65M85.43M31.75M
Total Assets
46.99M28.27M66.31M107.73M102.29M49.14M
Total Debt
394.31K20.88M25.09M26.59M26.84M9.45M
Net Debt
-41.35M7.16M8.09M1.58M-58.60M-22.30M
Total Liabilities
19.47M35.18M33.32M38.62M57.02M42.98M
Stockholders Equity
27.52M-6.90M32.99M69.11M45.27M6.16M
Cash FlowFree Cash Flow
-36.86M-36.10M-37.56M-48.24M-100.17M-48.46M
Operating Cash Flow
-36.86M-36.10M-37.54M-48.18M-99.69M-45.72M
Investing Cash Flow
-119.65M35.64M30.07M-73.42M-484.49K-2.74M
Financing Cash Flow
164.69M-2.82M-533.62K60.82M154.87M38.46M

Corbus Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.42
Price Trends
50DMA
9.62
Negative
100DMA
13.01
Negative
200DMA
29.47
Negative
Market Momentum
MACD
-0.91
Negative
RSI
28.73
Positive
STOCH
18.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 6.42 is below the 20-day moving average (MA) of 7.46, below the 50-day MA of 9.62, and below the 200-day MA of 29.47, indicating a bearish trend. The MACD of -0.91 indicates Negative momentum. The RSI at 28.73 is Positive, neither overbought nor oversold. The STOCH value of 18.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.

Corbus Pharmaceuticals Risk Analysis

Corbus Pharmaceuticals disclosed 51 risk factors in its most recent earnings report. Corbus Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Corbus Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$4.10B22.7281.65%63.39%
66
Neutral
$1.57B-9.85%56.60%-403.56%
59
Neutral
$537.90M-182.71%432.03%14.41%
49
Neutral
$6.84B0.05-53.14%2.48%24.49%-3.26%
46
Neutral
$421.09M91.25%-12.26%32.86%
32
Underperform
$83.79M-51.32%58.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CRBP
Corbus Pharmaceuticals
6.42
-38.71
-85.77%
AKBA
Akebia Therapeutics
1.69
0.32
23.36%
ADMA
ADMA Biologics
17.91
11.89
197.51%
ANAB
AnaptysBio
16.84
-6.76
-28.64%
KNSA
Kiniksa Pharmaceuticals
22.16
1.81
8.89%

Corbus Pharmaceuticals Corporate Events

Business Operations and StrategyFinancial Disclosures
Corbus Pharmaceuticals Reports Q4 2024 Financial Results
Neutral
Mar 11, 2025

Corbus Pharmaceuticals reported its Q4 and 2024 financial results, highlighting significant progress in its oncology and obesity programs. The company announced encouraging Phase 1 results for CRB-701 in Western studies, with the FDA granting Fast Track designation for its use in metastatic cervical cancer. The company also plans to start a study for CRB-913 in March 2025. Financially, Corbus reported a net loss of $9.5 million for Q4 2024, with $149 million in cash and investments, expected to fund operations through Q3 2027.

Product-Related AnnouncementsBusiness Operations and Strategy
Corbus Pharmaceuticals Reports Promising Phase 1 Trial Results
Positive
Feb 14, 2025

On February 14, 2025, Corbus Pharmaceuticals announced data from a Phase 1 clinical trial for CRB-701, presented at the ASCO GU Symposium. The trial in the US and UK showed promising safety and efficacy, with no dose-limiting toxicities and encouraging responses in several tumor types, including a first-time exploration in head and neck squamous cell carcinoma. This positions Corbus strongly within the oncology field, potentially impacting stakeholders positively.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.